Annual FCF
-$27.23 M
+$48.69 M+64.13%
31 December 2023
Summary:
Y-mAbs Therapeutics annual free cash flow is currently -$27.23 million, with the most recent change of +$48.69 million (+64.13%) on 31 December 2023. During the last 3 years, it has risen by +$64.17 million (+70.21%). YMAB annual FCF is now -143.88% below its all-time high of -$11.17 million, reached on 31 December 2016.YMAB Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$10.66 M
-$10.96 M-3678.86%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly free cash flow is currently -$10.66 million, with the most recent change of -$10.96 million (-3678.86%) on 30 September 2024. Over the past year, it has dropped by -$9.33 million (-697.09%). YMAB quarterly FCF is now -3678.86% below its all-time high of $298.00 thousand, reached on 30 June 2024.YMAB Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$21.88 M
-$9.33 M-74.30%
30 September 2024
Summary:
Y-mAbs Therapeutics TTM free cash flow is currently -$21.88 million, with the most recent change of -$9.33 million (-74.30%) on 30 September 2024. Over the past year, it has increased by +$5.98 million (+21.46%). YMAB TTM FCF is now -231.11% below its all-time high of -$6.61 million, reached on 31 March 2018.YMAB TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +64.1% | -697.1% | +21.5% |
| 3 y3 years | +70.2% | +41.2% | +74.8% |
| 5 y5 years | +34.3% | +51.5% | +65.5% |
YMAB Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +73.7% | -3678.9% | +68.9% | -74.3% | +78.9% |
| 5 y | 5 years | at high | +73.7% | -3678.9% | +68.9% | -74.3% | +78.9% |
| alltime | all time | -143.9% | +73.7% | -3678.9% | +68.9% | -231.1% | +78.9% |
Y-mAbs Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.66 M(-3678.9%) | -$21.88 M(+74.3%) |
| June 2024 | - | $298.00 K(-108.6%) | -$12.55 M(-28.6%) |
| Mar 2024 | - | -$3.48 M(-56.7%) | -$17.59 M(-35.4%) |
| Dec 2023 | -$27.23 M(-64.1%) | -$8.04 M(+500.6%) | -$27.23 M(-2.2%) |
| Sept 2023 | - | -$1.34 M(-71.7%) | -$27.86 M(-39.1%) |
| June 2023 | - | -$4.73 M(-63.9%) | -$45.75 M(-28.6%) |
| Mar 2023 | - | -$13.12 M(+51.5%) | -$64.12 M(-15.5%) |
| Dec 2022 | -$75.92 M(-26.7%) | -$8.66 M(-55.0%) | -$75.92 M(-25.3%) |
| Sept 2022 | - | -$19.23 M(-16.7%) | -$101.58 M(+1.1%) |
| June 2022 | - | -$23.10 M(-7.3%) | -$100.49 M(+4.5%) |
| Mar 2022 | - | -$24.93 M(-27.4%) | -$96.19 M(-7.1%) |
| Dec 2021 | -$103.52 M | -$34.32 M(+89.1%) | -$103.52 M(+19.1%) |
| Sept 2021 | - | -$18.15 M(-3.5%) | -$86.94 M(-6.6%) |
| June 2021 | - | -$18.80 M(-41.7%) | -$93.05 M(-8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$32.26 M(+81.9%) | -$101.89 M(+11.5%) |
| Dec 2020 | -$91.41 M(+21.1%) | -$17.74 M(-26.8%) | -$91.41 M(-8.0%) |
| Sept 2020 | - | -$24.25 M(-12.3%) | -$99.39 M(+2.3%) |
| June 2020 | - | -$27.64 M(+26.9%) | -$97.16 M(+16.2%) |
| Mar 2020 | - | -$21.78 M(-15.3%) | -$83.64 M(+10.8%) |
| Dec 2019 | -$75.46 M(+82.0%) | -$25.73 M(+16.9%) | -$75.46 M(+19.1%) |
| Sept 2019 | - | -$22.01 M(+55.9%) | -$63.37 M(+25.2%) |
| June 2019 | - | -$14.12 M(+3.7%) | -$50.60 M(+4.4%) |
| Mar 2019 | - | -$13.61 M(-0.2%) | -$48.46 M(+16.9%) |
| Dec 2018 | -$41.46 M(+161.3%) | -$13.63 M(+47.5%) | -$41.46 M(+49.0%) |
| Sept 2018 | - | -$9.24 M(-22.9%) | -$27.83 M(+49.7%) |
| June 2018 | - | -$11.98 M(+81.3%) | -$18.59 M(+181.3%) |
| Mar 2018 | - | -$6.61 M | -$6.61 M |
| Dec 2017 | -$15.87 M(+42.1%) | - | - |
| Dec 2016 | -$11.17 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual free cash flow?
- What is the all time high annual FCF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual FCF year-on-year change?
- What is Y-mAbs Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly FCF year-on-year change?
- What is Y-mAbs Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM FCF year-on-year change?
What is Y-mAbs Therapeutics annual free cash flow?
The current annual FCF of YMAB is -$27.23 M
What is the all time high annual FCF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual free cash flow is -$11.17 M
What is Y-mAbs Therapeutics annual FCF year-on-year change?
Over the past year, YMAB annual free cash flow has changed by +$48.69 M (+64.13%)
What is Y-mAbs Therapeutics quarterly free cash flow?
The current quarterly FCF of YMAB is -$10.66 M
What is the all time high quarterly FCF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly free cash flow is $298.00 K
What is Y-mAbs Therapeutics quarterly FCF year-on-year change?
Over the past year, YMAB quarterly free cash flow has changed by -$9.33 M (-697.09%)
What is Y-mAbs Therapeutics TTM free cash flow?
The current TTM FCF of YMAB is -$21.88 M
What is the all time high TTM FCF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM free cash flow is -$6.61 M
What is Y-mAbs Therapeutics TTM FCF year-on-year change?
Over the past year, YMAB TTM free cash flow has changed by +$5.98 M (+21.46%)